Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.82M | 45.36M | 48.17M | 46.83M | 44.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.82M | 45.36M | 48.17M | 46.83M | 44.62M |
| Cost of Revenue | 14.82M | 15.89M | 16.17M | 15.90M | 15.31M |
| Gross Profit | 27.00M | 29.47M | 32.00M | 30.94M | 29.31M |
| SG&A Expenses | 20.73M | 21.99M | 21.45M | 21.14M | 20.13M |
| Depreciation & Amortization | -- | -- | -- | -- | 27.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.24M | 38.62M | 38.33M | 37.71M | 36.10M |
| Operating Income | 5.58M | 6.73M | 9.83M | 9.12M | 8.52M |
| Income Before Tax | 5.11M | 5.87M | 8.92M | 7.96M | 7.07M |
| Income Tax Expenses | -1.00K | 14.00K | 18.00K | 4.00K | 17.00K |
| Earnings from Continuing Operations | 5.11 | 5.86 | 8.90 | 7.96 | 7.05 |
| Earnings from Discontinued Operations | -298.00K | -280.00K | -247.00K | -244.00K | -185.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.81M | 5.58M | 8.65M | 7.71M | 6.86M |
| EBIT | 5.58M | 6.73M | 9.83M | 9.12M | 8.52M |
| EBITDA | 5.98M | 7.11M | 10.18M | 9.42M | 8.80M |
| EPS Basic | 0.98 | 1.16 | 1.86 | 1.65 | 1.57 |
| Normalized Basic EPS | 0.72 | 0.83 | 1.27 | 1.13 | 1.01 |
| EPS Diluted | 0.00 | 0.34 | 1.04 | 1.15 | 1.57 |
| Normalized Diluted EPS | 0.02 | 0.25 | 0.68 | 0.76 | 1.01 |
| Average Basic Shares Outstanding | 17.68M | 17.64M | 17.60M | 17.55M | 17.47M |
| Average Diluted Shares Outstanding | 109.55M | 86.27M | 86.25M | 62.93M | 17.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |